The Role of the MSL in Clinical Trial Enrollment with Dan Hennessy PhD

02/01/24 • 36 min

Having a clinical trial that is properly supported and engaged is no easy feat, but accomplishing this can greatly improve the success of your asset. In this episode, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Dan Hennessy PhD, Vice President of Medical Affairs at Merus N.V., meet for a second time to discuss MSL and stakeholder engagement. They delve more specifically into the key role that Medical Affairs plays in accelerating and improving clinical trial enrollment and highlight how to use MSLs and a Field Medical team in different ways to ensure that you get the most value from the team, both from a US and a Global perspective. As they conclude, they explore what kinds of skills are required of a well-prepared Field Medical team and how to ensure they are properly prepared.

Previous Episode

Podcast Bytes - The Digital Transformation of Medical Affairs with Christian Dimaano, PhD, MPH

Medical Affairs is going through a digital transformation. What this means, what it will look like, and what value it will bring to pharmaceutical and biotech companies is still unknown. In this third episode of our short form podcast series, we discuss this topic with Christian Dimaano, PhD, MPH. As the VP, Head of Medical Affairs at Kinnate Biopharma, he has a wealth of Medical Affairs experience and insights. This conversation brings us further along in trying to understand the changes that are coming to the industry.

Next Episode

The Patient Impact in Drug Development and Value Demonstration with Len Lichtenfeld, MD, MACP

Now, more than ever, the patient voice is being heard by the pharmaceutical industry. In this episode, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, and Len Lichtenfeld, MD, MACP meet to discuss the ways patients are providing advisement in drug development and valuation. After hearing about Len’s extensive experience, they delve into the new regulatory changes coming to pharma and biotech that will require the patient experience to be taken into consideration during the drug development process. They conclude by discussing how the patient experience is having an impact on the valuation of new drugs.